Vertex Pharmaceuticals Incorpor found using ticker (VRTX) have now 19 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 254 and 183 calculating the mean target price we have 216.37. With the stocks previous close at 169.55 this indicates there is a potential upside of 27.6%. The day 50 moving average is 178.51 and the 200 day MA is 176.87. The market capitalisation for the company is $43,087m. Company Website: http://www.vrtx.com
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies; Moderna Therapeutics; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem; Janssen Pharmaceuticals; Merck KGaA; and Kymera Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.